ArticleArchives of microbiology2026
Antibacterial potential of marine sponge-associated fungus Amesia atrobrunnea strain AF5 against multidrug-resistant Gram-positive bacteria.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address the contemporary escalating challenge of antimicrobial resistance (AMR) pathogens, this study aimed to explore marine-associated fungi as a source of antibacterial metabolites against multidrug-resistant (MDR) bacteria. Ten different fungi were isolated from five diverse marine samples collected from the Narara Reef region of Gujarat, India, and subsequently evaluated for their antagonistic activity against a broad range of bacterial pathogens. Among the ten isolates, the sponge-associated fungal strain AF5 demonstrated potent antagonistic activity against seven Gram-positive bacterial pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE). However, no significant antagonistic activity was observed against the Gram-negative bacterial pathogens tested. Further morphological, molecular, and phylogeny analyses based on Internal Transcribed Spacer sequencing (ITS), Large Subunit (LSU), and beta-tubulin (tub2) loci identified the fungal isolate AF5 as Amesia atrobrunnea. Optimization studies revealed that among the four media tested, potato dextrose broth and Czapek yeast extract broth supported the highest antibiotic production, yielding inhibition zones of 24.62 ± 1.2 mm and 24.84 ± 0.5 mm, respectively, after 16 days of incubation. Among the solvents tested, chloroform exhibited the highest extraction efficiency, producing the largest inhibition zone (24.12 ± 0.3 mm) and an extraction yield of 2.814 ± 0.641 mg/g. The crude chloroform extract displayed notable antibacterial activity, producing inhibition zones of 15.00 ± 0.00 mm against multidrug-resistant Staphylococcus aureus (MDRSA) and 9.00 ± 1.00 mm against Multidrug-resistant Enterococcus faecalis (MDREF). It also displayed potent antibacterial activity at the lowest concentration against MRSA with MIC 3.90 µg/mL, MBC 7.81 µg/mL, and moderate activity against VRE with MIC and MBC 31.25 µg/mL. Further, GC-MS analysis of the bioactive TLC fractions C3 and C4 revealed 2,4-di-tert-butylphenol, tris(2,4-di-tert-butylphenyl) phosphate, and 7,9-di-tert-butyl-1-oxaspiro(4,5)deca-6,9-diene-2,8-dione as the predominant compounds potentially associated with the observed antibacterial activity. To our knowledge, this is the first report of a marine-derived Amesia atrobrunnea strain (AF5) producing bioactive metabolites with potent antibacterial activity against Gram-positive multidrug-resistant (MDR) pathogens.
Indexed as
Identifiers
42479174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.